Kathleen A Cooney

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9015420/publications.pdf

Version: 2024-02-01

157 papers	14,992 citations	41323 49 h-index	19169 118 g-index
162 all docs	162 docs citations	162 times ranked	19277 citing authors

#	Article	IF	Citations
1	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	13.5	2,660
2	REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. American Journal of Human Genetics, 2016, 99, 877-885.	2.6	1,555
3	A common variant associated with prostate cancer in European and African populations. Nature Genetics, 2006, 38, 652-658.	9.4	738
4	Multiple regions within 8q24 independently affect risk for prostate cancer. Nature Genetics, 2007, 39, 638-644.	9.4	621
5	Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14068-14073.	3.3	575
6	Germline Mutations inHOXB13and Prostate-Cancer Risk. New England Journal of Medicine, 2012, 366, 141-149.	13.9	566
7	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	9.4	492
8	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics, 2009, 41, 1116-1121.	9.4	389
9	Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genetics, 1995, 9, 439-443.	9.4	380
10	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics, 2011, 43, 785-791.	9.4	265
11	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. European Urology, 2017, 71, 740-747.	0.9	256
12	Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors. Neoplasia, 2015, 17, 385-399.	2.3	212
13	Prostate cancer in young men: an important clinical entity. Nature Reviews Urology, 2014, 11, 317-323.	1.9	206
14	Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nature Genetics, 2011, 43, 570-573.	9.4	198
15	Prostate Cancer Susceptibility Locus on Chromosome 1q: a Confirmatory Study. Journal of the National Cancer Institute, 1997, 89, 955-959.	3.0	193
16	Somatic Single Hits Inactivate the X-Linked Tumor Suppressor FOXP3 in the Prostate. Cancer Cell, 2009, 16, 336-346.	7.7	190
17	Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent. Prostate Cancer, 2013, 2013, 1-12.	0.4	180
18	Risk Factors for Lower Urinary Tract Symptoms in a Population-based Sample of African-American Men. American Journal of Epidemiology, 2003, 157, 906-914.	1.6	174

#	Article	IF	Citations
19	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
20	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of Clinical Oncology, 2018, 36, 991-999.	0.8	169
21	HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Human Genetics, 2013, 132, 5-14.	1.8	166
22	Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology, 1999, 54, 607-611.	0.5	156
23	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	0.8	155
24	Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome. Journal of Clinical Oncology, 2013, 31, 1713-1718.	0.8	144
25	A Combined Genomewide Linkage Scan of 1,233 Families for Prostate Cancerâ€“Susceptibility Genes Conducted by the International Consortium for Prostate Cancer Genetics. American Journal of Human Genetics, 2005, 77, 219-229.	2.6	138
26	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	1.4	118
27	Risk of second primary tumors in men diagnosed with prostate cancer: A populationâ€based cohort study. Cancer, 2014, 120, 2735-2741.	2.0	105
28	Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Menâ€™s Health Study. Urology, 2003, 61, 1086-1091.	0.5	91
29	Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 nearBRCA1. Prostate, 2003, 57, 326-334.	1.2	90
30	Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 23-32.	1.1	88
31	Features of the metabolic syndrome and prostate cancer in African-American men. Cancer, 2007, 109, 875-881.	2.0	83
32	Sexual Behavior, Sexually Transmitted Diseases and Prostatitis: The Risk of Prostate Cancer in Black Men. Journal of Urology, 2006, 176, 1108-1113.	0.2	77
33	Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design. Clinical Genitourinary Cancer, 2006, 4, 299-302.	0.9	73
34	Combined Genome-Wide Scan for Prostate Cancer Susceptibility Genes. Journal of the National Cancer Institute, 2004, 96, 1240-1247.	3.0	72
35	Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Investigational New Drugs, 2012, 30, 749-757.	1.2	72
36	Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology, 2002, 59, 362-367.	0.5	69

#	Article	IF	Citations
37	Tissue Microarray Assessment of Prostate Cancer Tumor Proliferation in African- American and White Men. Journal of the National Cancer Institute, 2000, 92, 937-939.	3.0	68
38	Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology, 2001, 57, 91-96.	0.5	67
39	Early onset prostate cancer has a significant genetic component. Prostate, 2012, 72, 147-156.	1.2	65
40	Genetic polymorphisms inCYP17,CYP3A4,CYP19A1,SRD5A2,IGF-1, andIGFBP-3 and prostate cancer risk in African-American men: The Flint Men's Health Study. Prostate, 2008, 68, 296-305.	1.2	60
41	Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics, 2016, 17, 231-240.	0.6	59
42	Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Human Genetics, 2006, 120, 471-485.	1.8	57
43	A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. Prostate, 2018, 78, 607-615.	1.2	57
44	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	1.1	56
45	Genetic variation in Glutathione S-Transferase Omega-1, Arsenic Methyltransferase and Methylene-tetrahydrofolate Reductase, arsenic exposure and bladder cancer: a caseâ€“control study. Environmental Health, 2012, 11, 43.	1.7	55
46	Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate, 2002, 53, 322-329.	1.2	53
47	The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Menâ€™s Health Study. Journal of Human Genetics, 2008, 53, 220-226.	1.1	52
48	Analysis of the Prostate Cancerâ€“Susceptibility Locus HPC20 in 172 Families Affected by Prostate Cancer. American Journal of Human Genetics, 2001, 68, 795-801.	2.6	51
49	Hereditary prostate cancer as a feature of Lynch Syndrome. Familial Cancer, 2011, 10, 37-42.	0.9	51
50	Role of the Nijmegen Breakage Syndrome 1 Gene in Familial and Sporadic Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 935-938.	1.1	49
51	Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Investigational New Drugs, 2011, 29, 1432-1440.	1.2	49
52	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	5.1	48
53	THE NATURAL HISTORY OF LOWER URINARY TRACT SYMPTOMS IN BLACK AMERICAN MEN: RELATIONSHIPS WITH AGING, PROSTATE SIZE, FLOW RATE AND BOTHERSOMENESS. Journal of Urology, 2001, 165, 1521-1525.	0.2	47
54	The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1366-1372.	1.1	47

#	Article	IF	Citations
55	Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Human Genetics, 2015, 134, 439-450.	1.8	45
56	Germline genetic variants in men with prostate cancer and one or more additional cancers. Cancer, 2017, 123, 3925-3932.	2.0	45
57	Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate, 2006, 66, 173-179.	1.2	42
58	EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor. Breast Cancer Research and Treatment, 2008, 107, 235-242.	1.1	41
59	HOXB13 G84Eâ€“related Familial Prostate Cancers. American Journal of Surgical Pathology, 2014, 38, 615-626.	2.1	41
60	Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. European Urology Oncology, 2020, 3, 224-230.	2.6	41
61	Chromosome 17q12 Variants Contribute to Risk of Early-Onset Prostate Cancer. Cancer Research, 2008, 68, 6492-6495.	0.4	40
62	Common Variation in the BRCA1 Gene and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1510-1516.	1.1	37
63	Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. Human Genetics, 2016, 135, 923-938.	1.8	37
64	Identifying Susceptibility Genes for Prostate Cancer--A Family-Based Association Study of Polymorphisms in CYP17, CYP19, CYP11A1, and LH-Â. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2035-2039.	1.1	36
65	Analysis of the gene coding for the BRCA2â€‹interacting protein PALB2 in hereditary prostate cancer. Prostate, 2008, 68, 675-678.	1.2	36
66	Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. European Urology, 2021, 79, 419-426.	0.9	36
67	Association between Agent Orange and prostate cancer: a pilot case-control study. Urology, 2004, 63, 757-760.	0.5	35
68	Truncating BRCA1 Mutations Are Uncommon in a Cohort of Hereditary Prostate Cancer Families with Evidence of Linkage to 17q Markers. Clinical Cancer Research, 2004, 10, 5975-5980.	3.2	34
69	Risk perception and concern among brothers of men with prostate carcinoma. Cancer, 2004, 100, 1537-1544.	2.0	34
70	Body Composition and Serum Prostate-Specific Antigen: Review and Findings from Flint Menâ€™s Health Study. Urology, 2008, 71, 554-560.	0.5	33
71	Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men. Prostate, 2009, 69, 956-960.	1.2	32
72	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. European Urology, 2020, 78, 316-320.	0.9	32

#	Article	IF	Citations
73	Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Human Molecular Genetics, 2007, 16, 1271-1278.	1.4	31
74	Fine-mapping the putative chromosome 17q21â€“22 prostate cancer susceptibility gene to a 10ÂcM region based on linkage analysis. Human Genetics, 2007, 121, 49-55.	1.8	30
75	Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. Urology, 2004, 63, 282-287.	0.5	28
76	Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. European Urology, 2021, 79, 353-361.	0.9	28
77	Genomeâ€wide linkage scan for prostate cancer susceptibility from the university of michigan prostate cancer genetics project: Suggestive evidence for linkage at 16q23. Prostate, 2009, 69, 385-391.	1.2	27
78	Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. Journal of Clinical Oncology, 2020, 38, 1807-1813.	0.8	27
79	Potential selection bias in a community-based study of PSA levels in African-American men. Journal of Clinical Epidemiology, 2001, 54, 142-148.	2.4	26
80	Genome-Wide Association Scan for Variants Associated with Early-Onset Prostate Cancer. PLoS ONE, 2014, 9, e93436.	1.1	25
81	Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Human Genetics, 2014, 133, 347-356.	1.8	24
82	Chromosome 8q24 markers: Risk of early-onset and familial prostate cancer. International Journal of Cancer, 2008, 122, 2876-2879.	2.3	23
83	Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. Breast Cancer Research and Treatment, 2015, 152, 163-172.	1.1	23
84	Genomeâ€wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for prostate cancer Genetics using novel sumLINK and sumLOD analyses. Prostate, 2010, 70, 735-744.	1.2	22
85	Comprehensive serial molecular profiling of an â€œN of 1â€•exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment. Journal of Hematology and Oncology, 2015, 8, 109.	6.9	22
86	Genome-wide linkage scan for prostate cancer susceptibility genes in men with aggressive disease: significant evidence for linkage at chromosome 15q12. Human Genetics, 2006, 119, 400-407.	1.8	21
87	Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). Human Genetics, 2012, 131, 1095-1103.	1.8	21
88	Prevalence of the <scp>HOXB13</scp>â€…<scp>G84E</scp> prostate cancer risk allele in men treated with radical prostatectomy. BJU International, 2014, 113, 830-835.	1.3	21
89	CD38 in Advanced Prostate Cancers. European Urology, 2021, 79, 736-746.	0.9	21
90	Clonality of sarcomatous and carcinomatous elements in sarcomatoid carcinoma of the prostate. Urology, 2006, 67, 423.e5-423.e8.	0.5	20

#	Article	IF	Citations
91	Evidence for an association between prostate cancer and chromosome 8q24 and 10q11 genetic variants in African American men: The flint men's health study. Prostate, 2011, 71, 225-231.	1.2	20
92	Rare germline mutations in African American men diagnosed with earlyâ€onset prostate cancer. Prostate, 2018, 78, 321-326.	1.2	20
93	R726L androgen receptor mutation is uncommon in prostate cancer families in the united states. Prostate, 2003, 54, 306-309.	1.2	19
94	Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Letters, 2008, 270, 173-180.	3.2	19
95	Sequence variation in Î±â€methylacylâ€CoA racemase and risk of earlyâ€onset and familial prostate cancer. Prostate, 2007, 67, 1507-1513.	1.2	18
96	Bayesian inference for the stereotype regression model: Application to a caseâ€“control study of prostate cancer. Statistics in Medicine, 2009, 28, 3139-3157.	0.8	18
97	Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer. Prostate, 2014, 74, 983-990.	1.2	18
98	Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: The Flint Menâ€™s Health Study. Urology, 2004, 64, 959-965.	0.5	16
99	Hyperglycemia, Obesity, and Cancer Risks on the Horizon. JAMA - Journal of the American Medical Association, 2005, 293, 235.	3.8	16
100	Two-locus genome-wide linkage scan for prostate cancer susceptibility genes with an interaction effect. Human Genetics, 2006, 118, 716-724.	1.8	16
101	Mutational landscape of candidate genes in familial prostate cancer. Prostate, 2014, 74, 1371-1378.	1.2	16
102	Prostate cancer early detection practices among men with a family history of disease. Urology, 2003, 62, 470-475.	0.5	15
103	Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer. Familial Cancer, 2012, 11, 595-600.	0.9	15
104	Prevalence and Correlates of Vitamin and Supplement Usage Among Men With a Family History of Prostate Cancer. Integrative Cancer Therapies, 2012, 11, 83-89.	0.8	14
105	Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. Prostate, 2012, 72, 410-426.	1.2	14
106	Association between family history of prostate and breast cancer among African-American men with prostate cancer. Urology, 2006, 68, 1072-1076.	0.5	13
107	Statin Use and the Risk of Recurrence After Radical Prostatectomy in a Cohort of Men With Inherited and/or Early-onset Forms of Prostate Cancer. Urology, 2014, 83, 1356-1361.	0.5	13
108	HOXB13 and other high penetrant genes for prostate cancer. Asian Journal of Andrology, 2016, 18, 530.	0.8	13

#	Article	IF	Citations
109	The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients. British Journal of Cancer, 2022, 126, 791-796.	2.9	13
110	Testing for the Recurrent HOXB13 G84E Germline Mutation in Men with Clinical Indications for Prostate Biopsy. Journal of Urology, 2013, 189, 849-853.	0.2	12
111	Germline mutations in PPFIBP2 are associated with lethal prostate cancer. Prostate, 2018, 78, 1222-1228.	1.2	12
112	Prostate Cancer Predisposition. Urologic Clinics of North America, 2021, 48, 283-296.	0.8	12
113	Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis. European Urology, 2016, 70, 209-210.	0.9	11
114	Genetic factors influencing prostate cancer risk in Norwegian men. Prostate, 2018, 78, 186-192.	1.2	11
115	Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank. British Journal of Cancer, 2020, 123, 1356-1359.	2.9	11
116	Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact. Transactions of the American Clinical and Climatological Association, 2017, 128, 14-23.	0.9	11
117	RE: OSTEOPOROSIS AFTER ORCHIECTOMY FOR PROSTATE CANCER. Journal of Urology, 1998, 160, 1809-1809.	0.2	10
118	Observed evidence for guidelineâ€recommended genes in predicting prostate cancer risk from a large populationâ€based cohort. Prostate, 2021, 81, 1002-1008.	1.2	10
119	Truncating Variants in p53AIP1 Disrupting DNA Damageâ€“Induced Apoptosis Are Associated with Prostate Cancer Risk. Cancer Research, 2006, 66, 10302-10307.	0.4	9
120	gsSKAT: Rapid gene set analysis and multiple testing correction for rareâ€variant association studies using weighted linear kernels. Genetic Epidemiology, 2017, 41, 297-308.	0.6	9
121	Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines. Cancer Epidemiology, 2018, 56, 112-117.	0.8	9
122	Family history of prostate cancer and relapse after definitive external beam radiation therapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 371-376.	0.4	8
123	APC I1307K and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 468-473.	1.1	8
124	Phase II Evaluation of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Patients with Hormone-Sensitive Prostate Adenocarcinoma. Clinical Genitourinary Cancer, 2007, 5, 318-322.	0.9	8
125	What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. Prostate, 2020, 80, 441-450.	1.2	8
126	Metastatic Dedifferentiated Chordoma With Elevated Î²-hCG. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 274-276.	0.6	7

#	Article	IF	Citations
127	INSPstI polymorphism and prostate cancer in African-American men. Prostate, 2005, 65, 83-87.	1.2	7
128	Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer. JCO Precision Oncology, 2020, 4, 139-151.	1.5	7
129	A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy. Advances in Radiation Oncology, 2016, 1, 59-66.	0.6	6
130	Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer Center. Journal of Cancer Education, 2017, 32, 871-877.	0.6	6
131	Mitochondrial alterations may underlie race-specific differences in cancer risk and outcome. Journal of Clinical Investigation, 2019, 129, 2187-2188.	3.9	6
132	Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. BMC Medical Genetics, 2012, 13, 46.	2.1	5
133	Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Caseâ€Control Sequencing Studies. Genetic Epidemiology, 2016, 40, 461-469.	0.6	5
134	Provider Practice Competition and Adoption of Medicareâ€™s Oncology Care Model. Medical Care, 2020, 58, 154-160.	1.1	5
135	Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, 332-339.e2.	0.9	5
136	Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families. Prostate, 2005, 64, 60-66.	1.2	4
137	Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Cancer, 2006, 106, 2617-2623.	2.0	4
138	Association between Germline Variation in the FHIT Gene and Prostate Cancer in Caucasians and African Americans. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1294-1297.	1.1	4
139	Association of germline rare pathogenic mutations in guidelineâ€recommended genes with prostate cancer progression: A metaâ€analysis. Prostate, 2022, 82, 107-119.	1.2	4
140	Assessing the Cumulative Contribution of New and Established Common Genetic Risk Factors to Early-Onset Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 766-772.	1.1	3
141	Abstract 5569: The association between statin use and risk of biochemical recurrence in men treated with radical prostatectomy in a cohort of men with inherited forms of prostate cancer. Cancer Research, 2011, 71, 5569-5569.	0.4	3
142	KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression. Prostate Cancer and Prostatic Diseases, 2022, , .	2.0	3
143	HOXB13 mutations and prostate cancer risk. BJU International, 2016, 118, 496-497.	1.3	2
144	Factors associated with appropriate and low-value PSA testing. Cancer Epidemiology, 2020, 66, 101724.	0.8	2

#	Article	IF	Citations
145	Semiparametric Bayesian modeling of random genetic effects in familyâ€based association studies. Statistics in Medicine, 2009, 28, 113-139.	0.8	1
146	Advances in inherited cancers: Introduction. Seminars in Oncology, 2016, 43, 527.	0.8	1
147	Finding a Needle in the Haystack: The Search for Germline Variants Associated with Prostate Cancer Clinical Outcomes. European Urology, 2018, 74, 720-721.	0.9	1
148	THE NATURAL HISTORY OF LOWER URINARY TRACT SYMPTOMS IN BLACK AMERICAN MEN: RELATIONSHIPS WITH AGING, PROSTATE SIZE, FLOW RATE AND BOTHERSOMENESS. Journal of Urology, 2001, , 1521-1525.	0.2	1
149	Editorial Comment. Journal of Urology, 2017, 197, 66-66.	0.2	0
150	Broadening the View of Germline Mutations in Kidney Cancer. JAMA Oncology, 2018, 4, 1235.	3.4	0
151	â€œSheroesâ€ Celebrating Women in Medicine Month During the Time of COVID-19. Academic Medicine, 2021, 96, e17-e18.	0.8	0
152	Germline mutations in DNA damage repair genes and HOXB13 among African American men diagnosed with early-onset prostate cancer.. Journal of Clinical Oncology, 2021, 39, 10505-10505.	0.8	0
153	Abstract 1642: Rare missense variants inMAP3K14andARHGAP27in men with hereditary prostate cancer. , 2012, , .		0
154	Abstract 2564: Identification of a novel SPOP missense mutation from targeted next-generation sequencing of men with chromosome 17-q linkage.. , 2013, , .		0
155	Abstract 1585: Application of a graphene oxide based microfluidic device (GO Chip) to prostate cancer circulating tumor cell capture and analysis. , 2015, , .		0
156	Abstract B40: Rare variant discovery in known cancer genes from whole-exome sequencingof African American hereditary prostate cancer families. , 2016, , .		0
157	Relative risks of prostate cancer associated with different family cancer histories.. Journal of Clinical Oncology, 2019, 37, 1505-1505.	0.8	0